Genetic analysis should be included in clinical practice when screening for antithrombin deficiency

Summary

Antithrombin (AT) deficiency increases the risk of thrombosis. Current evidence shows that some SERPINC1 mutations responsible for antithrombin deficiency often present a slightly decreased or normal activity and therefore could not be detected by functional tests. This study was designed to compare activity assays and direct genetic analyses in identifying hereditary antithrombin deficiency. In total, 400 consecutive patients with venous thrombosis were enrolled. Functional assays showed that 16 of the 400 individuals had decreased antithrombin activity, and 14 of them were confirmed by genetic analysis. Of the remaining 384 patients, 95 individuals without a known risk factor and 95 individuals with predisposing factors were also selected for gene sequencing. Eight additional causative mutations were identified in nine individuals and they should also be considered as antithrombin deficiency. In addition, a recurrent mutation, p.Arg356_Phe361del, was characterised. The mutant appeared to have a partially impaired secretion and a reduction in functional activity by 50 %. This study indicated that including genetic analysis in screening tests for identifying antithrombin deficiency was essential. Specifically, a genetic analysis of SERPINC1 is strongly recommended when individuals experience unprovoked thrombotic diseases, even if the AT activities are normal.

Keywords

Antithrombin deficiency - mutation - genetic - thrombosis - activity assay

^* These authors contributed equally to this work.

• References

• 1 Perry DJ, Carrell RW. Molecular genetics of human antithrombin deficiency. Human Mutation 1996; 07: 7-22..
• 2 Stevic I, Chan HH, Chander A. et al. Covalently linking heparin to antithrombin enhances prothrombinase inhibition on activated platelets. Thromb Haemost 2013; 109: 1016-1024.
• 3 Yang L, Manithody C, Qureshi SH. et al. Contribution of exosite occupancy by heparin to the regulation of coagulation proteases by antithrombin. Thromb Haemost 2010; 103: 277-283.
• 4 Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia 2008; 14: 1229-1239.
• 5 Bock SC, Wion KL, Vehar GA. et al. Cloning and expression of the cDNA for human antithrombin III. Nucleic Acids Res 1982; 10: 8113-8125.
• 6 Zhu T, Ding Q, Bai X. et al. Normal ranges and genetic variants of antithrombin, protein C and protein S in the general Chinese population. Results of the Chinese Hemostasis Investigation on Natural Anticoagulants Study I Group. Hae-matologica 2011; 96: 1033-1040.
• 7 Kim HJ, Seo JY, Lee KO. et al. Distinct frequencies and mutation spectrums of genetic thrombophilia in Korea in comparison with other Asian countries both in patients with thromboembolism and in the general population. Haematologi-ca 2014; 99: 561-569.
• 8 Tait RC, Walker ID, Perry DJ. et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87: 106-112.
• 9 van Boven HH, Vandenbroucke JP, Briet E. et al. Gene-gene and gene-environment interactions determine risk of thrombosis in families with inherited anti-thrombin deficiency. Blood 1999; 94: 2590-2594.
• 10 Luxembourg B, Pavlova A, Geisen C. et al. Impact of the type of SERPINC1 mutation and subtype of antithrombin deficiency on the thrombotic phenotype in hereditary antithrombin deficiency. Thromb Haemost 2014; 111: 249-257.
• 11 Khor B, Van Cott EM. Laboratory tests for antithrombin deficiency. Am J He-matol 2010; 85: 947-950.
• 12 Castaldo G, Cerbone AM, Guida A. et al. Molecular analysis and genotype-phe-notype correlation in patients with antithrombin deficiency from Southern Italy. Thromb Haemost 2012; 107: 673-680.
• 13 Luxembourg B, Delev D, Geisen C. et al. Molecular basis of antithrombin deficiency. Thromb Haemost 2011; 105: 635-646.
• 14 Di Perna P, Vecchione G, D‘Andrea G. et al. Identification of six novel mutations in type I antithrombin deficient Italian families. Haematologica 2004; 89: 117-118.
• 15 Fischer R, Sachs UJ, Heidinger KS. et al. Prevalence of hereditary antithrombin mutations is higher than estimated in patients with thrombotic events. Blood Coagul Fibrinol 2013; 24: 444-448.
• 16 Tang L, Guo T, Yang R. et al. Genetic background analysis of protein C deficiency demonstrates a recurrent mutation associated with venous thrombosis in Chinese population. PLoS One 2012; 07: e35773.
• 17 Tang L, Wang HF, Lu X. et al. Common genetic risk factors for venous thrombosis in the Chinese population. American journal of human genetics 2013; 92: 177-187.
• 18 Picard V, Chen JM, Tardy B. et al. Detection and characterisation of large SER-PINC1 deletions in type I inherited antithrombin deficiency. Human Genetics 2010; 127: 45-53.
• 19 Adzhubei IA, Schmidt S, Peshkin L. et al. A method and server for predicting damaging missense mutations. Nature Methods 2010; 07: 248-249.
• 20 Schwarz JM, Rodelsperger C, Schuelke M. et al. MutationTaster evaluates disease-causing potential of sequence alterations. Nature Methods 2010; 07: 575-576.
• 21 Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009; 04: 1073-1081.
• 22 McCoy AJ, Pei XY, Skinner R. et al. Structure of beta-antithrombin and the effect of glycosylation on antithrombin’s heparin affinity and activity. J Mol Biol 2003; 326: 823-833.
• 23 Kurihara M, Watanabe K, Inoue S. et al. Characterization of two novel mutations of the antithrombin gene observed in Japanese thrombophilic patients. Thromb Res 2005; 115: 351-358.
• 24 Tang L, Jian XR, Hamasaki N. et al. Molecular basis of protein S deficiency in China. Am J Hematol 2013; 88: 899-905.
• 25 Mitsuguro M, Sakata T, Okamoto A. et al. Usefulness of antithrombin deficiency phenotypes for risk assessment of venous thromboembolism: type I deficiency as a strong risk factor for venous thromboembolism. Intern J Hematol 2010; 92: 468-473.
• 26 Corral J, Hernandez-Espinosa D, Soria JM. et al. Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood 2007; 109: 4258-4263.
• 27 Roldan V, Ordonez A, Marin F. et al. Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis. Thromb Hae-most 2009; 101: 483-486.
• 28 Perry DJ, Daly ME, Tait RC. et al. Antithrombin cambridge II (Ala384Ser): clinical, functional and haplotype analysis of 18 families. Thromb Haemost 1998; 79: 249-253.
• 29 Chang JY, Tran TH. Antithrombin III Basel. Identification of a Pro-Leu substitution in a hereditary abnormal antithrombin with impaired heparin cofactor activity. J Biol Chem 1986; 261: 1174-1176.
• 30 Puurunen M, Salo P, Engelbarth S. et al. Type II antithrombin deficiency caused by a founder mutation Pro73Leu in the Finnish population: clinical picture. J Thromb Haemost 2013; 11: 1844-1849.
• 31 Daly M, Bruce D, Perry DJ. et al. Antithrombin Dublin (-3 Val----Glu): an N-terminal variant which has an aberrant signal peptidase cleavage site. FEBS letters 1990; 273: 87-90.
• 32 Ungerstedt JS, Schulman S, Egberg N. et al. Discrepancy between antithrombin activity methods revealed in Antithrombin Stockholm: do factor Xa-based methods overestimate antithrombin activity in some patients?. Blood 2002; 99: 2271-2272.
• 33 Javela K, Engelbarth S, Hiltunen L. et al. Great discrepancy in antithrombin activity measured using five commercially available functional assays. Thromb Res 2013; 132: 132-137.
• 34 Cooper PC, Coath F, Daly ME. et al. The phenotypic and genetic assessment of antithrombin deficiency. Intern J Lab Hematol 2011; 33: 227-237.
• 35 Kristensen SR, Rasmussen B, Pedersen S. et al. Detecting antithrombin deficiency may be a difficult task--more than one test is necessary. J Thromb Haemost 2007; 05: 617-618.
• 36 Caspers M, Pavlova A, Driesen J. et al. Deficiencies of antithrombin, protein C and protein S - practical experience in genetic analysis of a large patient cohort. Thromb Haemost 2012; 108: 247-257.
• 37 Wu O, Robertson L, Twaddle S. et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 2006; 10: 1-110.